Effects of brexpiprazole treatment on extrapyramidal and cognitive symptoms in patients with Parkinson's disease

Puntos clave

• Improvement in cognitive symptoms was observed alongside reduced extrapyramidal symptoms.
• Significant reduction of 30% in UPDRS scores indicates notable progress for patients.
• Assessment involved patient evaluations over a six-month duration focusing on symptom management.
• Findings may enhance future treatment strategies for Parkinson's disease, although long-term effects remain uncertain.